Table 2. ADMET and SwissADME properties of oxazole compounds (1-6).
| Compound | log Kp (cm/s) | GI absorption | BBB permeant | Pgp substrate | CYP1A2 inhibitor | CYP2C19 inhibitor | CYP2C9 inhibitor | CYP2D6 inhibitor | CYP3A4 inhibitor |
| 1 | -6 | High | Yes | No | Yes | Yes | Yes | Yes | Yes |
| 2 | -5.58 | High | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 3 | -5.65 | High | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 4 | -5.98 | High | No | Yes | No | Yes | Yes | Yes | Yes |
| 5 | -5.12 | High | No | Yes | No | Yes | Yes | Yes | Yes |
| 6 | -6.28 | High | No | Yes | No | Yes | Yes | Yes | Yes |
| Azithromycin | -8.01 | Low | No | Yes | No | No | No | No | No |
| Sulfanilamide | -7.79 | High | No | No | No | No | No | No | No |
| Sulfamethoxazole | -7.21 | High | No | No | No | No | No | No | No |